Literature DB >> 28062196

Radiotherapeutic and surgical management of iris melanoma: A review.

Marko Popovic1, Iqbal Ike K Ahmed2, Julia DiGiovanni3, Carol L Shields4.   

Abstract

We compare outcomes following radiotherapeutic and surgical management of iris melanoma. End points included local tumor recurrence, metastases, and common complications. From an initial search that yielded 231 articles, we found 17 relevant studies with 761 eyes. The gender distribution was balanced with a mean age of 52 years. Most studies focused on either proton beam (49.4%) or plaque (31.4%) radiotherapy. Rates of local recurrence (range: 0%-8%) and metastatic development (0%-5%) were favorable following radiotherapy; however, common complications included cataract (36%-73%), glaucoma (3%-92%), and corneal conditions (0%-33%). A unique complication of proton beam radiotherapy was limbal stem cell deficiency (2%-33%). In contrast, iridectomy and comparable procedures showed similar rates of recurrence (0%-8%) and metastases (0% in one study), lower rates of postoperative cataract (0%-33%) and corneal conditions (2.3% in one study), and a greater incidence of photophobia (9%-25%). Following enucleation, one study of mostly advanced eyes demonstrated a higher rate of metastases (14%). Overall, despite a paucity of research in this setting, efficacy and safety outcomes remain favorable. Decision-making for management should be based on tumor size, location, angle seeding, secondary glaucoma, visual potential, and patient preference.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  enucleation; iris neoplasms; melanoma; radiotherapy; surgery

Mesh:

Year:  2017        PMID: 28062196     DOI: 10.1016/j.survophthal.2016.12.012

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  8 in total

Review 1.  [New treatment options for iridociliary tumors].

Authors:  J M Mor; K R Koch; V Kakkassery; C Cursiefen; L M Heindl
Journal:  Ophthalmologe       Date:  2019-04       Impact factor: 1.059

2.  Orbital recurrence of iris melanoma 21 years after enucleation.

Authors:  Emilie Bergeron; Nadia Lihimdi; Dan Bergeron; Solange Landreville
Journal:  BMJ Case Rep       Date:  2017-09-07

3.  Novel Eye Plaque Designs for Brachytherapy of Iris and Ciliary Body Melanoma and the First Clinical Application.

Authors:  Wu Liu; Jenna May Kim; Benjamin K Young; Ravinder Nath; Zhe Chen; Roy H Decker; Melvin A Astrahan; Renelle Pointdujour-Lim
Journal:  Ocul Oncol Pathol       Date:  2018-10-11

Review 4.  Plaque brachytherapy in iris and iridociliary melanoma: a systematic review of efficacy and complications.

Authors:  Saeed Karimi; Amir Arabi; Toktam Shahraki
Journal:  J Contemp Brachytherapy       Date:  2021-02-18

5.  Occupational radiation exposure and glaucoma and macular degeneration in the US radiologic technologists.

Authors:  Mark P Little; Cari M Kitahara; Elizabeth K Cahoon; Marie-Odile Bernier; Raquel Velazquez-Kronen; Michele M Doody; David Borrego; Jeremy S Miller; Bruce H Alexander; Steven L Simon; Dale L Preston; Craig Meyer; Martha S Linet; Nobuyuki Hamada
Journal:  Sci Rep       Date:  2018-07-11       Impact factor: 4.379

6.  Robotic assisted CyberKnife radiosurgery for the treatment of iris melanoma.

Authors:  Valerie Schmelter; Sarah Heidorn; Alexander Muacevic; Siegfried G Priglinger; Paul Foerster; Raffael Liegl
Journal:  Sci Rep       Date:  2021-03-11       Impact factor: 4.379

7.  Proton beam radiation for iris melanoma: case series and review of literature.

Authors:  Jasmine Alexandra Hauzinger; Georgios Blatsios; Gertrud Haas; Claus Zehetner; Luisa Velez-Escola; Yvonne Nowosielski; Christof Seifarth; Teresa Rauchegger; Bernhard Haider; Nikolaos E Bechrakis
Journal:  BMJ Open Ophthalmol       Date:  2021-12-23

8.  Clinical Outcomes after Surgical Resection Combined with Brachytherapy for Uveal Melanomas.

Authors:  Isabel Relimpio-López; Antonio Manuel Garrido-Hermosilla; Francisco Espejo; María Gessa-Sorroche; Lourdes Coca; Belen Domínguez; María Jesús Díaz-Granda; Beatriz Ponte; María José Cano; Enrique Rodríguez de la Rúa; Francisco Carrasco-Peña; Carlos Míguez; Jonathan Saavedra; Antonio Ontanilla; Carlos Caparrós-Escudero; Juan José Ríos; José Antonio Terrón
Journal:  J Clin Med       Date:  2022-03-15       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.